A Lassa virus mRNA vaccine confers protection but does not require neutralizing antibody in a guinea pig model of infection

18Citations
Citations of this article
36Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Lassa virus is a member of the Arenaviridae family, which causes human infections ranging from asymptomatic to severe hemorrhagic disease with a high case fatality rate. We have designed and generated lipid nanoparticle encapsulated, modified mRNA vaccines that encode for the wild-type Lassa virus strain Josiah glycoprotein complex or the prefusion stabilized conformation of the Lassa virus glycoprotein complex. Hartley guinea pigs were vaccinated with two 10 µg doses, 28 days apart, of either construct. Vaccination induced strong binding antibody responses, specific to the prefusion conformation of glycoprotein complex, which were significantly higher in the prefusion stabilized glycoprotein complex construct group and displayed strong Fc-mediated effects. However, Lassa virus-neutralizing antibody activity was detected in some but not all animals. Following the challenge with a lethal dose of the Lassa virus, all vaccinated animals were protected from death and severe disease. Although the definitive mechanism of protection is still unknown, and assessment of the cell-mediated immune response was not investigated in this study, these data demonstrate the promise of mRNA as a vaccine platform against the Lassa virus and that protection against Lassa virus can be achieved in the absence of virus-neutralizing antibodies.

References Powered by Scopus

Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine

7599Citations
N/AReaders
Get full text

Suppression of RNA recognition by Toll-like receptors: The impact of nucleoside modification and the evolutionary origin of RNA

1812Citations
N/AReaders
Get full text

Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability

1263Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Advances in the design and delivery of RNA vaccines for infectious diseases

9Citations
N/AReaders
Get full text

Influence of glycosylation on the immunogenicity and antigenicity of viral immunogens

9Citations
N/AReaders
Get full text

mRNA vaccines for infectious diseases — advances, challenges and opportunities

7Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Ronk, A. J., Lloyd, N. M., Zhang, M., Atyeo, C., Perrett, H. R., Mire, C. E., … Bukreyev, A. (2023). A Lassa virus mRNA vaccine confers protection but does not require neutralizing antibody in a guinea pig model of infection. Nature Communications, 14(1). https://doi.org/10.1038/s41467-023-41376-6

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 9

53%

Researcher 6

35%

Professor / Associate Prof. 1

6%

Lecturer / Post doc 1

6%

Readers' Discipline

Tooltip

Veterinary Science and Veterinary Medic... 5

33%

Pharmacology, Toxicology and Pharmaceut... 4

27%

Biochemistry, Genetics and Molecular Bi... 4

27%

Agricultural and Biological Sciences 2

13%

Article Metrics

Tooltip
Mentions
Blog Mentions: 1
News Mentions: 1

Save time finding and organizing research with Mendeley

Sign up for free